TGFB1 and Nephropathy: SB525334 has shown an anti-fibrotic effects in different pathological models associated with the TGF-β signaling pathway, such as nephropathy [44,45], pulmonary fibrosis [46], and hepatic injury [47], as well as ovarian cancer [48], pancreatic cancer [49], and hepatocellular carcinoma [50].